Jim Breitmeyer

Jim Breitmeyer is a seasoned biopharmaceutical executive with extensive leadership experience, currently serving as the President, CEO, and a director at Oncternal Therapeutics, Inc. since its founding in September 2015. Previous roles include a member of the Board of Directors at Otonomy, Inc. (2018-2022) and Zogenix (2012-2022), where significant contributions included guiding Zogenix through an FDA Advisory Committee hearing for Zohydro. Prior experience also encompasses serving as President of ImmunoOncology and Corporate Executive Vice President at Bavarian Nordic and as Executive VP of Development and Chief Medical Officer at Cadence Pharmaceuticals. Early career highlights include a Vice President role at Eli Lilly and Company, where Jim Breitmeyer built a development team at Applied Molecular Evolution, and serving as a Scientific Advisor at ImmunoGen, Inc. Educational achievements include a fellowship in Oncology from Harvard Medical School, an MD and PhD in Medicine and Immunology from Washington University in St. Louis, and a BA in Chemistry and Biology from the University of California, Santa Cruz.